Hologic Inc. (HOLX) Stock

Hologic Inc. trades at a P/E ratio of 27.86, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 14.75 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 1.48 indicates reasonable value when growth is considered.

With a beta of 0.57, Hologic Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 3.09 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Hologic Inc. achieves a profit margin of 13.80%, meaning it retains $13.80 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 25.50% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 11.40% and ROA at 6.69%, the company achieves moderate returns on invested capital.

Hologic Inc.'s revenue grew by 1.20% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 4.90% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against MEDICAL INSTRUMENTS & SUPPLIES industry averages for proper context.

Hologic Inc. has a market capitalization of $14.9B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 222.42M shares outstanding, the company's ownership is relatively concentrated. As a participant in the MEDICAL INSTRUMENTS & SUPPLIES industry, it competes with other firms in this sector.

Hologic Inc.'s book value per share is $21.79, while the current stock price is $73.95, resulting in a price-to-book (P/B) ratio of 3.39. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

20 analysts cover HOLX with 45% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $72.43 implies -2.1% downside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:4 Strong Buy, 5 Buy, 11 Hold, 00The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.